0001415889-23-011952.txt : 20230808 0001415889-23-011952.hdr.sgml : 20230808 20230808210518 ACCESSION NUMBER: 0001415889-23-011952 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shafer Christina CENTRAL INDEX KEY: 0001934412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36576 FILM NUMBER: 231153133 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER, SUITE 500 STREET 2: 100 MATSONFORD ROAD CITY: RADNOR STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001267813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 484-801-4670 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031022 4 1 form4-08082023_090810.xml X0508 4 2023-08-07 0001267813 MARINUS PHARMACEUTICALS, INC. MRNS 0001934412 Shafer Christina 5 RADNOR CORPORATE CENTER, SUITE 500 100 MATSONFORD RD RADNOR PA 19087 false true false false CHIEF COMMERCIAL OFFICER 1 Common Stock 2023-08-07 4 S 0 2385 9.52 D 40637 D Common Stock 2023-08-08 4 S 0 11 8.93 D 40626 D The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.35 to $9.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. /s/ Debra A. Mohollen, Attorney-in-Fact 2023-08-08